Phase I Randomized Placebo Controlled Double Blind SAD and MAD Study of Oral AHRO-001 to Assess Safety, Tolerability and PK in Volunteers w/Mild/Moderate Hypercholesteremia

Trial Profile

Phase I Randomized Placebo Controlled Double Blind SAD and MAD Study of Oral AHRO-001 to Assess Safety, Tolerability and PK in Volunteers w/Mild/Moderate Hypercholesteremia

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2014

At a glance

  • Drugs Hyodeoxycholic acid (Primary) ; Atorvastatin
  • Indications Atherosclerosis; Hypercholesterolaemia
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors AtheroNova; CardioNova
  • Most Recent Events

    • 19 Nov 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
    • 30 Jul 2014 According to an AtheroNova media release, recruiting has been initiated in the phase Ib portion of the study.
    • 30 Jul 2014 AtheroNova will remain blinded to data from the earlier Phase I cohorts until the completion of the Phase Ib portion of the study, at which time the top-line data will be presented together, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top